All companies
Alcon Inc. logo

What smart money is saying about Alcon Inc.Switzerland flag

ALC · Healthcare · Medical - Specialties · Market cap $32.85B

4 funds in our archive have pitched Alcon Inc., most recently Pershing Square Holdings, Ltd. in September 2026.

Company profile

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Get an email when a fund buys, sells or pitches it

Summarize with Warren AI

Fund signal · last 12 months

4 letters

Too few moves on Alcon Inc. yet for a clear signal

+3
Net flow
3 buys · 3 new positions · 100%0 sells

Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.

Position history

Between Q1 2025 and Q4 2026, 6 fund letters reported a position in Alcon Inc., with 3 buys (opened or added) and 1 sell (trimmed or exited).

Fund letters reporting a position in Alcon Inc., by quarter
QuarterLettersBoughtSoldTheses
Q4 20261100
Q3 20262103
Q2 20261101
Q2 20251000
Q1 20251010

Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.

Fund activity · 6 positions · 4 moves

Fund coverage · 4 theses

  • Alcon is held for 12% to 15% constant-currency EPS growth guidance, margin expansion, and a 17 times earnings multiple, its lowest ever and far below its historical high-20s, with room for multiple expansion.

    Read the full thesis
  • Alcon is presented as a leading ophthalmology franchise with strong assets, a defensible oligopoly position, a deep pipeline, and long-term growth drivers despite recent execution disappointments.

    Read the full thesis
  • Beck Mack & Oliver Portfolio
    July 2026

    Alcon has leading positions in cataract surgery and contact lenses, with strong pricing power and a valuation that does not reflect its sustainable mid-teens EPS growth.

    Read the full thesis
  • Alcon has a dominant ophthalmology franchise, attractive recurring revenue, margin expansion potential, and upside from AURN001.

    Read the full thesis

Read every full thesis on Alcon Inc.

Read all 4 theses in full, with each fund's reasoning, and get unlimited access to the archive.

View plans→
Share this ledger